Introduction

Name

• Silybin.

Class of drug

• Nutraceutical.
• Nutritional supplement.
• An active constituent of the extract silymarin from the milk thistle plantSilybum marianum.
• A flavonolignan.

Description

Chemical name

• Silybin A+B.

Molecular formula

• C25H22O10.

Molecular weight

• 482.44 g/mol.

Physical properties

• A crystalline solid.

Storage requirements

• Store in a cool, dry place.

Uses

Indications

• Management of hepatic and hepatobiliary disease.
• Treatment of certain hepatotoxins:
  • egAmanita phalloides(deathcap mushroom) poisoning   Mushroom poisoning  .
• Support of brain health including management of cognitive dysfunction   Feline cognitive dysfunction syndrome  .

Administration

Pharmacokinetics

Precautions

Interactions

with other drugs

• None reported.

Adverse Reactions

Further Reading

Publications

Refereed papers

• Recent references from PubMed and VetMedResource.
• Au A Y, Hasenwinkel J M, & Frondoza C G (2011) Silybin inhibits interleukin-1ß-induced production of pro-inflammatory mediators in canine hepatocyte cultures. J Vet Pharmacol Ther 34 (2), 120-129 PubMed.
• Al-Anati L, Essid E, Reinehr R, & Petzinger E (2009) Silibinin protects OTA-mediated TNF-alpha release from perfused rat livers and isolated rat Kupffer cells. Mol Nut Food Res 53 (4), 460-466.
• Webb C B, McCord K W, & Twedt D C (2009) Assessment of oxidative stress in leukocytes and granulocyte function following oral administration of a silibinin-phosphatidylcholine complex in cats. Am J Vet Res 70, 57-62.
• Crocenzi F A & Roma M G (2006) Silymarin as a new hepatoprotective agent in experimental cholestasis: new possibilities for an ancient medication. Curr Med Chem 13 (9), 1055-1074.
• Crocenzi F A, Sánchez Pozzi E J, Pelligrino J M, Rodríguez Garay E A, Mottino A D, & Roma M G (2003) Preventive effect of silymarin against taurolithocholate-induced cholestasis in the rat. Biochem Pharmacol 66 (2), 355-364.
• Crocenzi F A, Pelligrino J M, Sánchez Pozzi E J, Mottino A D, Rodríguez Garay E A, & Roma M G (2000) Effect of silymarin on biliary bile salt secretion in the rat. Biochem Pharmacol 59 (8), 1015-1022.
• Dehmlow C, Erhard J, & de Groot H (1996) Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 23 (4), 749-754.
• Dehmlow C, Murawski N, & de Groot (1996) Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci 58 (18), 1591-1600.
• Filburn C R, Kettenacker R, & Griffin D W (2007) Bioavailability of a silybin-phosphatidylcholine complex in dogs. J Vet Pharmacol Ther 30 (2), 132-138 PubMed.
• Webb C B, Gustafson D L, & Twedt D C (2012) Bioavailability following oral administration of a silybinin-phosphatidylcholine complex in cats. Intern J Appl Res Vet Med 20 (2), 107-112.
• Vogel G, Tuchweber B, Trost W, & Mengs U (1984) Protection by silibinin against Amanita phalloides intoxication in beagles .Toxicol App Pharmacol 73 (3), 355-362.